fruquintinib+paclitaxel

DRUG2 trials

Sponsors

Hutchison Medipharma Limited, Sun Yat-sen University

Conditions

Advanced Gastric CancerFruquintinibGastric CancerGastroesophageal Junction AdenocarcinomaRamucirumab

Phase 1

A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer

CompletedNCT02415023

Hutchison Medipharma LimitedGastric Cancer

Start: 2014-11-09End: 2017-03-31Updated: 2020-02-17

Unknown Phase

MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ Adenocarcinoma

Not yet recruitingNCT07144995

Sun Yat-sen UniversityAdvanced Gastric Cancer, Fruquintinib, Gastroesophageal Junction Adenocarcinoma +1

Start: 2025-09-05End: 2026-12-31Target: 1143Updated: 2025-08-28

Related Papers

Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma.

2026-08-12

Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma.

Journal of Clinical Oncology2026-01-10

Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTINEOGA) protocol

BMJ Open2024-02-016 citations

A Phase I/II trial of fruquintinib in combination with paclitaxel for second-line treatment in patients with advanced gastric cancer.

Journal of Clinical Oncology2017-02-0111 citations